Literature DB >> 17068063

Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience.

Paraskevi V Voulgari, Aliki I Venetsanopoulou, Efstratios K Epagelis, Yannis Alamanos, Ioanna Takalou, Alexandros A Drosos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17068063      PMCID： PMC1798489          DOI： 10.1136/ard.2006.058735

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  10 in total

Review 1.  Assessment of patients with psoriatic arthritis: a review of currently available measures.

Authors:  Dafna D Gladman; Philip Helliwell; Philip J Mease; Peter Nash; Christopher Ritchlin; William Taylor
Journal:  Arthritis Rheum       Date:  2004-01

2.  Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment.

Authors:  S N Nikas; P V Voulgari; I P Takalou; P Katsimbri; A A Drosos
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

3.  Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).

Authors:  Christian E Antoni; Arthur Kavanaugh; Bruce Kirkham; Zuhre Tutuncu; Gerd R Burmester; Udo Schneider; Daniel E Furst; Jerry Molitor; Edward Keystone; Dafna Gladman; Bernhard Manger; Siegfried Wassenberg; Ralf Weier; Daniel J Wallace; Michael H Weisman; Joachim R Kalden; Josef Smolen
Journal:  Arthritis Rheum       Date:  2005-04

4.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

5.  Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation.

Authors:  Christian Antoni; Claudia Dechant; P D Hanns-Martin Lorenz; Joerg Wendler; Alexandra Ogilvie; Mathias Lueftl; Dolores Kalden-Nemeth; Joachim R Kalden; Bernhard Manger
Journal:  Arthritis Rheum       Date:  2002-10-15

6.  Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.

Authors:  C Antoni; G G Krueger; K de Vlam; C Birbara; A Beutler; C Guzzo; B Zhou; L T Dooley; A Kavanaugh
Journal:  Ann Rheum Dis       Date:  2005-01-27       Impact factor: 19.103

Review 7.  Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality.

Authors:  D M Ashcroft; A L Wan Po; H C Williams; C E Griffiths
Journal:  Br J Dermatol       Date:  1999-08       Impact factor: 9.302

8.  Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis.

Authors:  T I Temekonidis; A N Georgiadis; Y Alamanos; D V Bougias; P V Voulgari; A A Drosos
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

9.  Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients.

Authors:  M Feletar; J E Brockbank; C T Schentag; V Lapp; D D Gladman
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

10.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

Authors:  D T Felson; J J Anderson; M Boers; C Bombardier; D Furst; C Goldsmith; L M Katz; R Lightfoot; H Paulus; V Strand
Journal:  Arthritis Rheum       Date:  1995-06
  10 in total
  3 in total

Review 1.  A case report of a psoriatic arthritis patient on hemodialysis treated with tumor necrosis factor blocking agent and a literature review.

Authors:  Ioanna Saougou; Charalampos Papagoras; Theodora E Markatseli; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Clin Rheumatol       Date:  2010-05-21       Impact factor: 2.980

2.  Ankylosing spondylitis: recent breakthroughs in diagnosis and treatment.

Authors:  Saeed A Shaikh
Journal:  J Can Chiropr Assoc       Date:  2007-12

Review 3.  Advances in nanomedicine for the treatment of ankylosing spondylitis.

Authors:  Yanhai Xi; Tingwang Jiang; Birendra Chaurasiya; Yanyan Zhou; Jiangmin Yu; Jiankun Wen; Yan Shen; Xiaojian Ye; Thomas J Webster
Journal:  Int J Nanomedicine       Date:  2019-10-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.